Publications by authors named "Isabelle Van Praagh"

Claim this Profile
M
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Judith Passildas-Jahanmohan, Jean-Christophe Eymard, Mélanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh

Cancer Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Study on Body Composition, Energy Balance and Biological Factors Changes in Post-menopausal Women with Breast Cancer Receiving Adjuvant Chemotherapy Including Taxanes.
Emilie Gadéa, Emilie Thivat, Pascale Dubray-Longeras, Marie Arbre, Isabelle Van-Praagh

Nutr Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments.
Angeline Ginzac, Émilie Thivat, Marie-Ange Mouret-Reynier, Pascale Dubray-Longeras, Isabelle Van Praagh

Clin Breast Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Hakim Mahammedi, Eloise Planchat, Mélanie Pouget, Xavier Durando, Hervé Curé, Isabelle Van-Praagh

Oncology· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Mélanie Pouget, Catherine Abrial, Eloise Planchat, Isabelle Van Praagh, Marie Arbre

Oncology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study.
Pierre Soubeyran, Carine Bellera, Jean Goyard, Damien Heitz, Hervé Curé, Isabelle van Praagh

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Jean-Marc Nabholtz, Marie-Ange Mouret-Reynier, Xavier Durando, Isabelle Van Praagh, Sana Al-Sukhun

Expert Opin Pharmacother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].
Marie-Ange Mouret-Reynier, Catherine Abrial, Marianne Leheurteur, Xavier Durando, Isabelle Van Praagh

Bull Cancer· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Catherine Abrial, Isabelle Van Praagh, Rémi Delva, Bernard Leduc, Joël Fleury

Oncologist· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Pierre Fargeot, Jacques Bonneterre, Henri Roché, Alain Lortholary, Mario Campone, Isabelle Van Praagh

J Clin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Jacques Bonneterre, Henri Roché, Pierre Kerbrat, Pierre Fumoleau, Marie-Josèphe Goudier, Isabelle Van Praagh

J Clin Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects.
Régine Minet-Quinard, Isabelle Van Praagh, Fabrice Kwiatkowski, Guy Beaujon, Viviane Feillel

Cancer Invest· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.
Isabelle Van Praagh, Hervé Cure, Bernard Leduc, Sabine Charrier, Guillaume Le Bouedec

Oncologist· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.
Sophie Amat, Frederique Penault-Llorca, Hervew Cure, Guillaume Le Bouedëc, Jean-Louis Achard, Isabelle Van Praagh

Int J Oncol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis